Perspective Therapeutics Past Earnings Performance
Past criteria checks 0/6
Perspective Therapeutics's earnings have been declining at an average annual rate of -45.7%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 8.7% per year.
Key information
-45.7%
Earnings growth rate
-7.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -8.7% |
| Return on equity | -49.8% |
| Net Margin | -2,611.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Perspective Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -37 | 21 | 21 |
| 30 Sep 23 | 6 | -29 | 25 | 16 |
| 30 Jun 23 | 6 | -23 | 24 | 11 |
| 31 Mar 23 | 6 | -14 | 20 | 6 |
| 31 Dec 22 | 5 | -8 | 9 | 2 |
| 30 Sep 22 | 10 | -9 | 11 | 3 |
| 30 Jun 22 | 0 | -6 | 6 | 1 |
| 31 Mar 22 | 11 | -6 | 9 | 2 |
| 31 Dec 21 | 11 | -6 | 9 | 2 |
| 30 Sep 21 | 10 | -5 | 8 | 2 |
| 30 Jun 21 | 10 | -3 | 7 | 1 |
| 31 Mar 21 | 10 | -4 | 7 | 1 |
| 31 Dec 20 | 10 | -3 | 7 | 1 |
| 30 Sep 20 | 10 | -3 | 7 | 1 |
| 30 Jun 20 | 10 | -3 | 8 | 1 |
| 31 Mar 20 | 9 | -3 | 7 | 1 |
| 31 Dec 19 | 8 | -4 | 7 | 1 |
| 30 Sep 19 | 8 | -4 | 7 | 1 |
| 30 Jun 19 | 7 | -5 | 7 | 1 |
| 31 Mar 19 | 7 | -6 | 7 | 2 |
| 31 Dec 18 | 7 | -7 | 7 | 2 |
| 30 Sep 18 | 6 | -7 | 7 | 2 |
| 30 Jun 18 | 6 | -7 | 7 | 2 |
| 31 Mar 18 | 6 | -6 | 7 | 1 |
| 31 Dec 17 | 5 | -6 | 7 | 1 |
| 30 Sep 17 | 5 | -6 | 6 | 1 |
| 30 Jun 17 | 5 | -6 | 6 | 1 |
| 31 Mar 17 | 5 | -6 | 6 | 1 |
| 31 Dec 16 | 4 | -5 | 5 | 1 |
| 30 Sep 16 | 5 | -5 | 5 | 1 |
| 30 Jun 16 | 5 | -5 | 5 | 1 |
| 31 Mar 16 | 5 | -5 | 5 | 1 |
| 31 Dec 15 | 5 | -4 | 5 | 0 |
| 30 Sep 15 | 5 | -4 | 4 | 1 |
| 30 Jun 15 | 5 | -4 | 4 | 1 |
| 31 Mar 15 | 4 | -4 | 4 | 1 |
| 31 Dec 14 | 4 | -5 | 4 | 1 |
| 30 Sep 14 | 4 | -5 | 4 | 1 |
| 30 Jun 14 | 4 | -7 | 4 | 1 |
| 31 Mar 14 | 4 | -6 | 4 | 1 |
| 31 Dec 13 | 5 | -5 | 4 | 1 |
| 30 Sep 13 | 4 | -5 | 4 | 1 |
| 30 Jun 13 | 5 | -4 | 4 | 1 |
Quality Earnings: CATX is currently unprofitable.
Growing Profit Margin: CATX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CATX is unprofitable, and losses have increased over the past 5 years at a rate of 45.7% per year.
Accelerating Growth: Unable to compare CATX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CATX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: CATX has a negative Return on Equity (-49.82%), as it is currently unprofitable.